Navigation Links
Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
Date:2/5/2008

BERKELEY, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), announced today that Peter M. Strumph, Chief Executive Officer, will present at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at 11:00 a.m. EST. Mr. Strumph will provide an overview of Nile and an update on its clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section at http://www.nilethera.com. The webcast will be archived for ninety days. Additional information regarding the BIO Investor Forum can be accessed at http://ceo.bio.org.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of acute decompensated heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the Company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Prospectus filed pursuant to Rule 424(b)(3) of the Securities Act of 1933, as amended, with the Securities and Exchange Commission on November 15, 2007. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
2. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
3. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
7. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
8. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
9. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
10. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
11. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... the three months ended December 31, 2016. ... and diagnostics company that develops and commercializes proprietary technologies and ... ... the commercial milestones achieved in fiscal 2016," said Andrew ...
(Date:2/21/2017)... ... 21, 2017 , ... Genedata, a leading provider of advanced ... establishment of Genedata Limited as a new subsidiary in the United Kingdom. The ... science informatics. Creating the UK subsidiary reinforces Genedata’s commitment to collaborate closely with ...
(Date:2/21/2017)... IL (PRWEB) , ... February ... ... of the Life -Sciences division, Treximo will pair its $200M operational capacity ... results-based consulting and project management in areas affecting quality and operational management. ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
Breaking Biology News(10 mins):